Abstract：Mammalian target of rapamycin (mTOR), a key regulator of cell metabolism and survival, regulates cell proliferation, survival and metabolism. More and more studies have shown that mTOR is a new therapeutic target for neurodegenerative diseases. mTOR is essential to the survival, development and differentiation of neurons. However, the molecular mechanism of mTOR-mediated neurodegenerative diseases is not fully understood. Here, we summarize recent research advances on the interplay between the mTOR signaling pathway and neurodegenerative diseases, and further discuss the potential role of mTOR in neurodegenerative diseases.
[1] Huang K, Fingar DC. Growing knowledge of the mTOR signaling network[J]. Semin Cell Dev Biol, 2014, 36:79-90. [2] Weichhart T. Mammalian target of rapamycin: a signaling kinase for every aspect of cellular life[J]. Methods Mol Biol, 2012, 821:1-14. [3] Kaur A, Sharma S. Mammalian target of rapamycin (mTOR) as a potential therapeutic target in various diseases[J]. Inflammopharmacology, 2017, 25(3):293-312. [4] Zhou H, Huang S. The complexes of mammalian target of rapamycin[J]. Curr Protein Pept Sci, 2010, 11(6):409-424. [5] Dunlop EA, Tee AR. Mammalian target of rapamycin complex 1: signalling inputs, substrates and feedback mechanisms[J]. Cell Signal, 2009, 21(6):827-835. [6] Wataya-Kaneda M. Mammalian target of rapamycin and tuberous sclerosis complex[J]. J Dermatol Sci, 2015, 79(2):93-100. [7] Tee A, Sampson JR, Pal DK, et al. The role of mTOR signalling in neurogenesis, insights from tuberous sclerosis complex[J].Semin Cell Dev Biol, 2016, 52:12-20. [8] Laplante M, Sabatini DM. Regulation of mTORC1 and its impact on gene expression at a glance[J]. J Cell Sci, 2013, 126(Pt 8):1713-1719. [9] Bracho-Valdés I, Moreno-Alvarez P, Valencia-Martínez I, et al. mTORC1- and mTORC2-interacting proteins keep their multifunctional partners focused[J]. IUBMB Life, 2011, 63(10):896-914. [10] Linke M, Fritsch SD, Sukhbaatar N, et al. mTORC1 and mTORC2 as regulators of cell metabolism in immunity[J]. FEBS Lett, 2017,591(19):389. [11] Crino PB. The mTOR signalling cascade: paving new roads to cure neurological disease[J]. Nat Rev Neurol, 2016, 12(7):379-392. [12] Wong M. Mammalian target of rapamycin (mTOR) pathways in neurological diseases[J]. Biomed J, 2013, 36(2):40-50. [13] Zhao ZC, Yan CS, Wang S, et al. Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin[J]. Prog Neurobiol, 2012, 99(2):128-148. [14] Switon K, Kotulska K, Janusz-Kaminska A, et al. Molecular neurobiology of mTOR[J]. Neuroscience, 2017, 341:112-153. [15] Laplante M, Sabatini DM. mTOR signaling in growth control and disease[J]. Cell, 149(2):274-293. [16] Lan AP, Chen J, Zhao Y, et al. mTOR Signaling in Parkinson’s Disease[J]. Neuromolecular Med, 2017, 19(1):1-10. [17] Sukhbaatar N, Hengstschläger M, Weichhart T. mTOR-mediated regulation ofdendriticcelldifferentiation and function[J]. Trends Immunol, 2016, 37(11):778-789. [18] Tian T, Sun Y, Wu H, et al. Acupuncture promotes mTOR-independent autophagic clearance of aggregation-prone proteins in mouse brain[J]. Sci Rep, 2016, 6:19714. [19] Perluigi M, Di DF, Butterfield DA. mTOR signaling in aging and neurodegeneration: At the crossroad between metabolism dysfunction and impairment of autophagy[J]. Neurobiol Dis, 2015, 84(1):39-49. [20] Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease[J]. Cell, 2017, 168(6):960-976. [21] Williams A, Sarkar S, Cuddon P, et al. Novel targets for Huntington’s disease in an mTOR-independent autophagy pathway[J]. Nat Chem Biol, 2008, 4(5):295-305. [22] Ravikumar B, Vacher C, Berger Z, et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease[J]. Nat Genet, 2004, 36(6):585-595.
2018, Vol. 25 
